ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...

ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...

Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...

Leuprolide acetate 7.5mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal area ...

Read the Medication Guide provided by your pharmacist before you start using leuprolide and each time you get a refill. If you have any questions, ask your doctor or pharmacist. This medication is ...

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer. Abbott announced Monday the approval of a 45-mg, six-month ...

Leuprolide acetate 45mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal area, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot. It is indicated for palliative treatment of advanced prostate cancer. Leuprolide ...

The US Food and Drug Administration (FDA) have approved Abbott’s supplemental New Drug Application (sNDA) for Lupron Depot-PED (leuprolide acetate for depot suspension). The one-month formulation is ...

The FINANCIAL — Abbott Park, Illinois — Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot® ...

"Advanced prostate cancer can have a devastating impact on patients and their quality of life," says Dr. Andrew Loblaw, Clinician Scientist and Head of Genitourinary Radiation Oncology Clinical ...